ergotamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| ergot alkaloid derivatives | 1043 | 113-15-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 4 | mg | Inhal.aerosol |
| 4 | mg | O |
| 4 | mg | P |
| 4 | mg | R |
| 4 | mg | SL |
| 4 | mg | O |
| 4 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
| S (Water solubility) | 0.00 mg/mL | Bocci G, Oprea TI, Benet LZ |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.15 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 2 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 3.60 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 15 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.10 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 26, 1948 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ergot poisoning | 86.76 | 47.20 | 9 | 131 | 92 | 63488790 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ergot poisoning | 115.85 | 42.62 | 12 | 152 | 131 | 79744093 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N02CA02 | NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Ergot alkaloids |
| ATC | N02CA52 | NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Ergot alkaloids |
| ATC | N02CA72 | NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Ergot alkaloids |
| FDA CS | M0007665 | Ergotamines |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D000322 | Adrenergic Agonists |
| MeSH PA | D058646 | Adrenergic alpha-1 Receptor Agonists |
| MeSH PA | D000316 | Adrenergic alpha-Agonists |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D010120 | Oxytocics |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D012102 | Reproductive Control Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018490 | Serotonin Agents |
| MeSH PA | D017366 | Serotonin Receptor Agonists |
| MeSH PA | D014662 | Vasoconstrictor Agents |
| FDA EPC | N0000175766 | Ergotamine Derivative |
| CHEBI has role | CHEBI:25442 | mycotoxins |
| CHEBI has role | CHEBI:35569 | alpha-adrenergic agonists |
| CHEBI has role | CHEBI:35941 | serotonin agonists |
| CHEBI has role | CHEBI:36063 | oxytocic agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Migraine | indication | 37796009 | DOID:6364 |
| Vascular headache | indication | 128187005 | |
| Cluster headache syndrome | indication | 193031009 | |
| Cluster Headache Prevention | indication | ||
| Brain damage | contraindication | 2470005 | |
| Necrotizing enterocolitis in fetus OR newborn | contraindication | 2707005 | |
| Tachyarrhythmia | contraindication | 6285003 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
| Alcoholism | contraindication | 7200002 | |
| Hyperammonemia | contraindication | 9360008 | |
| Bacterial septicemia | contraindication | 10001005 | DOID:0040085 |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Chronic obstructive lung disease | contraindication | 13645005 | DOID:3083 |
| Hepatic encephalopathy | contraindication | 13920009 | DOID:13413 |
| Severe chronic ulcerative colitis | contraindication | 14311001 | |
| Toxic megacolon | contraindication | 28536002 | DOID:1770 |
| Atony of colon | contraindication | 29479008 | |
| Vascular surgery procedure | contraindication | 30904006 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Depressive disorder | contraindication | 35489007 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Complete trisomy 21 syndrome | contraindication | 41040004 | DOID:14250 |
| Hyperactive behavior | contraindication | 44548000 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Achalasia of esophagus | contraindication | 45564002 | DOID:9164 |
| Chronic heart failure | contraindication | 48447003 | |
| Retroperitoneal fibrosis | contraindication | 49120005 | |
| Fibrosis of lung | contraindication | 51615001 | DOID:3770 |
| Paralytic ileus | contraindication | 55525008 | DOID:8442 |
| Peptic reflux disease | contraindication | 57643001 | |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Diarrhea | contraindication | 62315008 | |
| Thrombophlebitis | contraindication | 64156001 | DOID:3875 |
| Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
| Poisoning by phenobarbital | contraindication | 64921004 | |
| Drug AND/OR toxin-induced diarrhea | contraindication | 65979008 | |
| Substance abuse | contraindication | 66214007 | |
| Agoraphobia | contraindication | 70691001 | DOID:593 |
| Hepatic coma | contraindication | 72836002 | DOID:12550 |
| Sleep apnea | contraindication | 73430006 | DOID:0050847 |
| Spastic paralysis | contraindication | 78403003 | |
| Disturbance of salivary secretion | contraindication | 78948009 | |
| Hiatal hernia | contraindication | 84089009 | DOID:12642 |
| Prinzmetal angina | contraindication | 87343002 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Seizure disorder | contraindication | 128613002 | |
| Autonomic dysreflexia | contraindication | 129618003 | |
| Bleeding | contraindication | 131148009 | |
| Obsessive-compulsive disorder | contraindication | 191736004 | DOID:10933 |
| Insomnia | contraindication | 193462001 | |
| Impaired renal function disorder | contraindication | 197663003 | |
| Myocardial dysfunction | contraindication | 233928007 | |
| Peripheral ischemia | contraindication | 233958001 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Sepsis syndrome | contraindication | 238150007 | |
| Pyloric obstruction | contraindication | 244815007 | |
| Sleep automatism | contraindication | 247962006 | |
| Raynaud's phenomenon | contraindication | 266261006 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Dyspnea | contraindication | 267036007 | |
| Retention of urine | contraindication | 267064002 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Drowsy | contraindication | 271782001 | |
| Cerebral ischemia | contraindication | 287731003 | |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Panic disorder | contraindication | 371631005 | DOID:594 |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Cardiovascular event risk | contraindication | 395112001 | |
| Gastric ulcer | contraindication | 397825006 | DOID:10808 |
| Peripheral vascular disease | contraindication | 400047006 | |
| Respiratory insufficiency | contraindication | 409623005 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Chronic lung disease | contraindication | 413839001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
| Myocardial infarction in recovery phase | contraindication | 418044006 | |
| Porphyria | contraindication | 418470004 | |
| Fibrosis of pleura | contraindication | 442110002 | |
| Hypertensive urgency | contraindication | 443482000 | |
| Acute exacerbation of asthma | contraindication | 708038006 | |
| Severe Pruritus | contraindication | ||
| Ergot Alkaloid Toxicity | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.58 | acidic |
| pKa2 | 12.56 | acidic |
| pKa3 | 13.71 | acidic |
| pKa4 | 6.51 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 1D | GPCR | AGONIST | Ki | 9.10 | CHEMBL | CHEMBL | |||
| Beta-1 adrenergic receptor | GPCR | Ki | 5.62 | DRUG MATRIX | |||||
| Beta-2 adrenergic receptor | GPCR | Ki | 5.72 | DRUG MATRIX | |||||
| D(1A) dopamine receptor | GPCR | Ki | 6.06 | DRUG MATRIX | |||||
| D(2) dopamine receptor | GPCR | Ki | 8.85 | DRUG MATRIX | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 9.10 | DRUG MATRIX | |||||
| Cytochrome P450 3A4 | Enzyme | IC50 | 6 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 9.35 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | AGONIST | Ki | 9 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2B | GPCR | AGONIST | Ki | 8.90 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2C | GPCR | AGONIST | Ki | 8.70 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 6 | GPCR | AGONIST | Ki | 8.60 | IUPHAR | ||||
| Alpha-1A adrenergic receptor | GPCR | AGONIST | WOMBAT-PK | ||||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 8.75 | DRUG MATRIX | |||||
| D(3) dopamine receptor | GPCR | Ki | 8.84 | DRUG MATRIX | |||||
| D(1B) dopamine receptor | GPCR | Ki | 6.77 | PDSP | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 6.06 | PDSP | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 6.04 | PDSP | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 8.68 | CHEMBL | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 8.74 | DRUG MATRIX | |||||
| Alpha-1D adrenergic receptor | GPCR | Ki | 8.49 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 5A | GPCR | Ki | 7.85 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1F | GPCR | AGONIST | Ki | 6.80 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 1E | GPCR | AGONIST | Ki | 6.30 | IUPHAR | ||||
| Tyrosine-protein kinase Lck | Kinase | IC50 | 5.19 | DRUG MATRIX | |||||
| Tyrosine-protein kinase Fyn | Kinase | IC50 | 5.50 | DRUG MATRIX | |||||
| Thromboxane-A synthase | Enzyme | IC50 | 5.51 | DRUG MATRIX | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 8.34 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 10.04 | DRUG MATRIX | |||||
| Alpha-1A adrenergic receptor | GPCR | IC50 | 8.09 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | IC50 | 9.11 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | AGONIST | Ki | 8 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 7 | GPCR | ANTAGONIST | Ki | 7.30 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2C | GPCR | AGONIST | Ki | 7.90 | IUPHAR | ||||
| Gastrin/cholecystokinin type B receptor | GPCR | IC50 | 4.77 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | AGONIST | Ki | 8.60 | IUPHAR | ||||
| Cholecystokinin A receptor | GPCR | IC50 | 4.47 | CHEMBL | |||||
| Adenylate cyclase | Unclassified | IC50 | 4.15 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 5A | GPCR | ANTAGONIST | Ki | 8.20 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 5A | GPCR | ANTAGONIST | Ki | 8.40 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 4 | GPCR | Ki | 6.58 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1F | GPCR | AGONIST | IC50 | 7.30 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4022407 | VUID |
| N0000020412 | NUI |
| D00679 | KEGG_DRUG |
| 379-79-3 | SECONDARY_CAS_RN |
| 4018515 | VANDF |
| 4022407 | VANDF |
| C0014710 | UMLSCUI |
| CHEBI:190463 | CHEBI |
| ERM | PDB_CHEM_ID |
| CHEMBL442 | ChEMBL_ID |
| CHEMBL2448612 | ChEMBL_ID |
| D004878 | MESH_DESCRIPTOR_UI |
| DB00696 | DRUGBANK_ID |
| 149 | IUPHAR_LIGAND_ID |
| 391 | INN_ID |
| 639-81-6 | SECONDARY_CAS_RN |
| PR834Q503T | UNII |
| 8223 | PUBCHEM_CID |
| 4025 | RXNORM |
| 44346 | MMSL |
| 4674 | MMSL |
| d00222 | MMSL |
| 000678 | NDDF |
| 004526 | NDDF |
| 32647002 | SNOMEDCT_US |
| 395975005 | SNOMEDCT_US |
| 396046007 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ERGOTAMINE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0143-2120 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 22 sections |
| MIGERGOT | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0713-0166 | SUPPOSITORY | 2 mg | RECTAL | ANDA | 14 sections |
| MIGERGOT | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0713-0166 | SUPPOSITORY | 2 mg | RECTAL | ANDA | 14 sections |
| Cafergot | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-5405 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 23 sections |
| Ergomar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10802-1202 | TABLET, ORALLY DISINTEGRATING | 2 mg | SUBLINGUAL | ANDA | 24 sections |
| ergotamine tartrate and caffeine | HUMAN PRESCRIPTION DRUG LABEL | 2 | 24470-917 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 24 sections |
| ERGOTAMINE TARTRATE, CAFFEINE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 52187-555 | TABLET | 1 mg | ORAL | ANDA | 12 sections |
| Ergomar Sublingual | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70720-120 | TABLET | 2 mg | ORAL | ANDA | 25 sections |
| Ergomar Sublingual | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70720-120 | TABLET | 2 mg | ORAL | ANDA | 25 sections |
| Migergot | HUMAN PRESCRIPTION DRUG LABEL | 2 | 75987-090 | SUPPOSITORY | 2 mg | RECTAL | ANDA | 22 sections |